Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18785860 | APPARATUS AND METHOD FOR GENERATING CLINICAL DECISION SUPPORT | July 2024 | April 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18649589 | VIRTUAL HEALTH COACH FOR FACILITATING DYNAMIC DOSAGE TITRATION | April 2024 | February 2025 | Allow | 9 | 1 | 0 | No | No |
| 18437817 | CONVERSATIONAL SERVICES FOR ARTIFICIAL INTELLIGENCE HEALTH SUPPORT | February 2024 | December 2024 | Allow | 10 | 1 | 0 | No | No |
| 18510890 | CUSTOMIZABLE DATA MANAGEMENT SYSTEM | November 2023 | September 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18110629 | REDUCING NETWORK TRAFFIC ASSOCIATED WITH GENERATING EVENT PREDICTIONS BASED ON COGNITIVE IMAGE ANALYSIS SYSTEMS AND METHODS | February 2023 | April 2025 | Allow | 26 | 1 | 0 | Yes | No |
| 18166251 | SYSTEMS AND METHODS FOR PATIENT TARGETED THERAPY DEVELOPMENT | February 2023 | August 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 18163732 | PERSONAL, OMIC, AND PHENOTYPE DATA COMMUNITY AGGREGATION PLATFORM | February 2023 | May 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18073550 | METHOD FOR AUTOIMMUNE DISEASE OR SPECIFIC CHRONIC DISEASE RISK EVALUATION, EARLY DETECTION AND TREATMENT SELECTION | December 2022 | May 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18007670 | METHODS FOR PREDICTING TREATMENT RESPONSE IN CANCERS | December 2022 | March 2025 | Allow | 28 | 1 | 0 | No | No |
| 17971796 | SYSTEMS AND METHODS FOR NETWORK-BASED COUNSELING | October 2022 | July 2024 | Allow | 21 | 1 | 0 | No | No |
| 17950966 | ESTIMATING PHARMACOKINETIC PARAMETERS USING DEEP LEARNING | September 2022 | June 2025 | Allow | 32 | 2 | 0 | Yes | No |
| 17950913 | SYSTEM AND METHOD OF LIMITED MOBILITY TRACKING | September 2022 | February 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17790140 | SYSTEM FOR PROVIDING GENETIC INFORMATION-BASED PERSONALIZED SOCIAL CONTENT INFORMATION, AND METHOD THEREOF | June 2022 | February 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17847904 | MONITORING OF ANOMALIES IN BEHAVIOR TO INCREASE QUALITY OF SOFTWARE DEVELOPMENT | June 2022 | May 2025 | Abandon | 35 | 2 | 0 | Yes | No |
| 17844614 | ATMOSPHERIC MIRRORING AND DYNAMICALLY VARYING THREE-DIMENSIONAL ASSISTANT ADDISON INTERFACE FOR INTERIOR ENVIRONMENTS | June 2022 | February 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 17757119 | METHOD AND SYSTEM FOR IMPROVING TREATMENT ADHERENCE LEVEL | June 2022 | December 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17782378 | Systems, Methods, and Media for Automatically Predicting a Classification of Incidental Adrenal Tumors Based on Clinical Variables and Urinary Steroid Levels | June 2022 | February 2025 | Allow | 33 | 2 | 0 | Yes | No |
| 17725918 | INTERACTION BETWEEN A MASK AND A PATIENT DURING THERAPY | April 2022 | April 2025 | Abandon | 36 | 2 | 0 | No | No |
| 17657044 | CUSTOMIZED EXCEPTIONS FOR INTELLIGENT PROTOCOLING | March 2022 | August 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17703226 | CLINICAL DECISION SUPPORT SYSTEM FOR ESTIMATING DRUG-RELATED TREATMENT OPTIMIZATION CONCERNING INFLAMMATORY DISEASES | March 2022 | January 2025 | Abandon | 34 | 2 | 0 | Yes | No |
| 17655917 | RECYCLING COMPONENTS IN MEDICAL DEVICES | March 2022 | August 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17697962 | ARTIFICIAL INTELLIGENCE-BASED DIFFICULT AIRWAY EVALUATION METHOD AND DEVICE | March 2022 | March 2025 | Abandon | 36 | 2 | 0 | No | No |
| 17761288 | APPARATUS, SYSTEM, METHOD, AND COMPUTER READABLE MEDIUM FOR REHABILITATION PLANNING USING MACHINE LEARNING | March 2022 | September 2024 | Allow | 30 | 1 | 0 | Yes | No |
| 17693151 | INTELLIGENT SECURE NETWORKED HEALTH MESSAGING SYSTEMS AND METHODS | March 2022 | October 2024 | Abandon | 31 | 1 | 0 | Yes | No |
| 17690117 | ARTIFICIAL INTELLIGENCE METHODS AND SYSTEMS FOR CONSTITUTIONAL ANALYSIS USING OBJECTIVE FUNCTIONS | March 2022 | August 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17685683 | MACHINE LEARNING MODELS FOR VEHICLE ACCIDENT POTENTIAL INJURY DETECTION | March 2022 | September 2024 | Allow | 30 | 2 | 0 | Yes | No |
| 17639797 | ASSISTIVE SYSTEM USING CRADLE | March 2022 | November 2024 | Abandon | 32 | 2 | 0 | No | No |
| 17665847 | SYSTEM, METHOD, AND GRAPHICAL USER INTERFACE FOR IDENTIFYING MEDICAL CARE PROVIDERS OUTSIDE A PROCESS-OF-CARE STANDARD | February 2022 | June 2024 | Allow | 28 | 2 | 0 | No | No |
| 17569692 | IDENTIFYING COMMON CARE GAPS BETWEEN PATIENT GROUPS | January 2022 | June 2025 | Allow | 41 | 3 | 0 | Yes | No |
| 17540459 | Methods and Systems for Managed Authorization Routing | December 2021 | December 2024 | Abandon | 37 | 2 | 0 | No | No |
| 17596015 | A METHOD OF EVALUATING AUTOIMMUNE DISEASE RISK AND TREATMENT SELECTION | December 2021 | December 2024 | Allow | 37 | 2 | 0 | Yes | No |
| 17456626 | Leveraging Blockchain to Secure Dialysis Components and Maintain Operational Logs | November 2021 | June 2024 | Allow | 31 | 1 | 0 | No | No |
| 17517885 | METHOD FOR PRESENTING THERAPY EVENTS ON A CONTINUOUS TIME-BASED DATA FEED | November 2021 | June 2024 | Allow | 32 | 2 | 0 | Yes | No |
| 17508322 | METHODS AND SYSTEMS FOR MICROSATELLITE ANALYSIS | October 2021 | May 2025 | Allow | 43 | 3 | 0 | Yes | No |
| 17384455 | INTERCOMMUNICATION AND COOPERATIVE OPERATION OF SURGICAL DEVICES | July 2021 | March 2024 | Allow | 32 | 1 | 0 | No | No |
| 17356699 | AUTOMATED PLACENTAL MEASUREMENT | June 2021 | December 2024 | Abandon | 42 | 1 | 0 | No | No |
| 16739667 | IDENTIFYING CANCER THERAPIES | January 2020 | March 2025 | Allow | 60 | 6 | 0 | Yes | No |
| 16507521 | METHOD AND SYSTEM TO AUTOMATE THE DESIGNATION OF THE INTERNATIONAL CLASSIFICATION OF DISEASE CODES FOR A PATIENT | July 2019 | March 2023 | Allow | 45 | 7 | 0 | No | No |
| 16506969 | PATIENT TRACKING AND DYNAMIC UPDATING OF PATIENT PROFILE | July 2019 | August 2024 | Allow | 60 | 8 | 0 | Yes | No |
| 16463871 | MEDICAL TOOLS MANAGEMENT SYSTEM AND METHODS FOR OPERATING SAME | May 2019 | June 2025 | Abandon | 60 | 7 | 0 | No | No |
| 15982992 | SYSTEM AND METHOD FOR MEDICAL RESOURCE UTILIZATION MANAGEMENT | May 2018 | March 2019 | Allow | 10 | 1 | 0 | No | No |
| 15887448 | METHODS AND SYSTEMS FOR COGNITIVE BEHAVIORAL THERAPY | February 2018 | April 2020 | Allow | 26 | 0 | 0 | No | No |
| 15746767 | SYSTEMS AND METHODS FOR ANALYZING HEALTHCARE DATA | January 2018 | October 2024 | Abandon | 60 | 6 | 0 | Yes | Yes |
| 14987947 | QUALITY VALUE UNIT SYSTEM AND METHOD | January 2016 | August 2023 | Abandon | 60 | 12 | 0 | No | No |
| 14810000 | MOBILE TERMINAL AND CONTROLLING METHOD THEREOF | July 2015 | August 2019 | Allow | 48 | 2 | 1 | Yes | No |
| 14688116 | NETWORK SYSTEM AND METHOD FOR CONTROLLING A COMPUTER TOMOGRAPH | April 2015 | July 2018 | Allow | 39 | 2 | 0 | No | No |
| 14560348 | FACILITATING HEALTH MANAGEMENT OF SUBJECTS | December 2014 | April 2020 | Allow | 60 | 2 | 0 | No | Yes |
| 13374748 | EVIDENCE-BASED HEALTHCARE INFORMATION MANAGEMENT PROTOCOLS | January 2012 | April 2019 | Allow | 60 | 9 | 0 | Yes | No |
| 12896275 | SYSTEM AND METHOD FOR INTEGRATED VERIFICATION AND ASSEMBLY OF MULTI-SCRIPT POUCHES INTO A HOUSING CONTAINER | October 2010 | August 2014 | Allow | 46 | 2 | 0 | No | No |
| 12668521 | LOCALIZATION METHOD FOR MOBILE ROBOTS BASED ON LANDMARKS | May 2010 | August 2014 | Allow | 56 | 3 | 0 | Yes | No |
| 12721043 | HEALTH QUALITY MEASURES SYSTEMS AND METHODS | March 2010 | April 2014 | Allow | 49 | 2 | 0 | Yes | No |
| 12596447 | APPARATUS AND METHODS FOR RENDERING PERSONAL STORIES TO MEDICAL PATIENTS | October 2009 | April 2014 | Allow | 54 | 2 | 0 | No | No |
| 11724227 | Database networks including advanced replication schemes | March 2007 | June 2017 | Abandon | 60 | 11 | 0 | Yes | No |
| 11473960 | Multi-user remote health monitoring system | June 2006 | February 2010 | Abandon | 44 | 5 | 0 | Yes | Yes |
| 10972000 | INFLUENCING COMMUNICATIONS AMONG A SOCIAL SUPPORT NETWORK | October 2004 | February 2010 | Allow | 60 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PAULS, JOHN A.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PAULS, JOHN A works in Art Unit 3683 and has examined 52 patent applications in our dataset. With an allowance rate of 65.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner PAULS, JOHN A's allowance rate of 65.4% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PAULS, JOHN A receive 2.63 office actions before reaching final disposition. This places the examiner in the 88% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by PAULS, JOHN A is 34 months. This places the examiner in the 25% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +25.8% benefit to allowance rate for applications examined by PAULS, JOHN A. This interview benefit is in the 76% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.6% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 18.8% of cases where such amendments are filed. This entry rate is in the 15% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 18% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 15% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 76.9% are granted (fully or in part). This grant rate is in the 91% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.9% of allowed cases (in the 76% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 37% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.